Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
B Cell
100%
Non-Hodgkin Lymphoma
100%
Rituximab
100%
Doxorubicin
100%
Cyclophosphamide
100%
Vincristine
100%
Progression Free Survival
75%
Overall Survival
75%
Cytarabine
50%
B-Cell Lymphoma
50%
Methotrexate
50%
Prednisone
50%
Etoposide
50%
Drug Megadose
25%
Diffuse Large B-Cell Lymphoma
25%
Autologous Stem Cell Transplantation
25%
Ifosfamide
25%
Experimental Therapy
25%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
25%
Dexamethasone
25%
High Dose Chemotherapy
25%
Cyclophosphamide Plus Doxorubicin Plus Etoposide Plus Prednisolone Plus Rituximab Plus Vincristine
25%
Diseases
25%
Pharmacology, Toxicology and Pharmaceutical Science
Nonhodgkin Lymphoma
100%
Rituximab
100%
Doxorubicin
100%
Cyclophosphamide
100%
Vincristine
100%
Progression Free Survival
75%
Overall Survival
75%
Prednisone
50%
Cytarabine
50%
B Cell Lymphoma
50%
Methotrexate
50%
Etoposide
50%
Dexamethasone
25%
Diffuse Large B Cell Lymphoma
25%
Ifosfamide
25%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
25%
High Dose Chemotherapy
25%
Cyclophosphamide Plus Doxorubicin Plus Etoposide Plus Prednisolone Plus Rituximab Plus Vincristine
25%
Diseases
25%
Keyphrases
Treatment Failure
100%
Frontline Treatment
100%
Immunochemotherapy
100%
Aggressive B-cell non-Hodgkin Lymphoma
100%
Rituximab
36%
Doxorubicin
36%
Cyclophosphamide
36%
Prednisone
18%
Overall Survival
18%
Median Progression-free Survival
18%
Cytarabine
18%
Aggressive B-cell Lymphoma
18%
Etoposide
18%
Early Treatment Failure
18%
Progression-free Survival
9%
Overall Response Rate
9%
Relapsed or Refractory
9%
Median Overall Survival
9%
Standard of Care
9%
Prolonged Survival
9%
Academic Center
9%
Poor Outcome
9%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
9%
First-line Therapy
9%
Complete Response
9%
Ifosfamide
9%
Burkitt
9%
Relapsed Disease
9%
Experimental Therapeutics
9%
Methotrexate
9%
R-CHOP
9%
High-dose Chemotherapy
9%
R-EPOCH
9%
Second-line Treatment
9%
Standard-of-care Therapy
9%
Platinum-based
9%
Primary Refractory
9%
Hyperfractionated
9%
Hyper-CVAD
9%
Late Treatment Failure
9%
High-dose Methotrexate (HD-MTX)
9%
Early Failure
9%
Refractory Diffuse Large B-cell Lymphoma
9%
Immunology and Microbiology
B Cell
100%
Rituximab
100%
Cyclophosphamide
100%
Overall Survival
75%
Progression Free Survival
75%
Drug Megadose
50%
Methotrexate
50%
Prednisone
50%
Dexamethasone
25%
Autologous Stem Cell Transplantation
25%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
25%
Cyclophosphamide Plus Doxorubicin Plus Etoposide Plus Prednisolone Plus Rituximab Plus Vincristine
25%